MicroRNA expression profiling of thymic epithelial tumors

Lung Cancer

Volumn 85, Issue 2, 2014, Pages 197-204

  Ganci, Federica ^a   Vico, Carmen ^b   Korita, Etleva ^a   Sacconi, Andrea ^a   Gallo, Enzo ^a   Mori, Federica ^a   Cambria, Annamaria ^c   Russo, Emanuele ^b,d   Anile, Marco ^b,d   Vitolo, Domenico ^b   Pescarmona, Edoardo ^a   Blandino, Rosario ^e   Facciolo, Francesco ^a   Venuta, Federico ^b,d   Blandino, Giovanni ^a   Marino, Mirella ^a   Fazi, Francesco ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c S Vincenzo Hospital   (Italy)

^d Fondazione Eleonora Lorillard Spencer Cenci   (Italy)

^e Department of Oncology Division of Oncological Surgery S Vincenzo Hospital   (Italy)

Author keywords

EGFR; MicroRNAs; MiR 145; Thymic epithelial tumors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 141 3P; MICRORNA 145; MICRORNA 145 5P; MICRORNA 148A 3P; MICRORNA 205 5P; MICRORNA 21 5P; MICRORNA 34B 5P; MICRORNA 486 5P; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; CARCINOGENESIS; DISEASE FREE SURVIVAL; DOWN REGULATION; EPITHELIUM TUMOR; HIGH RISK POPULATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW RISK POPULATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMIC EPITHELIAL TUMOR; THYMOMA; UPREGULATION; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; THYMUS;

CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS, GLANDULAR AND EPITHELIAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYMUS GLAND; THYMUS NEOPLASMS;

EID: 84904120786     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.04.008     Document Type: Article

References (38)

1. Venuta F., Rendina E.A., Anile M., de Giacomo T., Vitolo D., Coloni G.F. Thymoma and thymic carcinoma. Gen Thorac Cardiovasc Surg 2012, 60:1-12.
2. Kelly R.J., Petrini I., Rajan A., Wang Y., Giaccone G. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011, 29:4820-4827.
3. Rena O., Papalia E., Maggi G., Oliaro A., Ruffini E., Filosso P., et al. World Health Organization histologic classification: an independent prognostic factor in resected thymomas. Lung Cancer 2005, 50:59-66.
4. Girard N. Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol 2010, 5:S291-S295.
5. Petrini I., Meltzer P.S., Zucali P.A., Luo J., Lee C., Santoro A., et al. Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death Dis 2012, 3:e351.
6. Hirose Y., Kondo K., Takizawa H., Nagao T., Nakagawa Y., Fujino H., et al. Aberrant methylation of tumour-related genes in thymic epithelial tumours. Lung Cancer 2009, 64:155-159.
7. Kont V., Murumagi A., Tykocinski L.O., Kinkel S.A., Webster K.E., Kisand K., et al. DNA methylation signatures of the AIRE promoter in thymic epithelial cells, thymomas and normal tissues. Mol Immunol 2011, 49:518-526.
8. Girard N., Shen R., Guo T., Zakowski M.F., Heguy A., Riely G.J., et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009, 15:6790-6799.
9. Lee G.Y., Yang W.I., Jeung H.C., Kim S.C., Seo M.Y., Park C.H., et al. Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization. BMC Genomics 2007, 8:305.
10. Badve S., Goswami C., Gokmen-Polar Y., Nelson R.P., Henley J., Miller N., et al. Molecular analysis of thymoma. PLoS ONE 2012, 7:e42669.
11. Sasaki H., Ide N., Fukai I., Kiriyama M., Yamakawa Y., Fujii Y. Gene expression analysis of human thymoma correlates with tumor stage. Int J Cancer 2002, 101:342-347.
12. Petrini I., Rajan A., Pham T., Voeller D., Davis S., Gao J., et al. Whole genome and transcriptome sequencing of a b3 thymoma. PLoS ONE 2013, 8:e60572.
13. Gokmen-Polar Y., Cook R.W., Goswami C.P., Wilkinson J., Maetzold D., Stone J.F., et al. A gene signature to determine metastatic behavior in thymomas. PLoS ONE 2013, 8:e66047.
14. Weissferdt A., Lin H., Woods D., Tang X., Fujimoto J., Wistuba I.I., et al. HER family receptor and ligand status in thymic carcinoma. Lung Cancer 2012, 77:515-521.
15. Aisner S.C., Dahlberg S., Hameed M.R., Ettinger D.S., Schiller J.H., Johnson D.H., et al. Epidermal growth factor receptor C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J Thorac Oncol 2010, 5:885-892.
16. Yoh K., Nishiwaki Y., Ishii G., Goto K., Kubota K., Ohmatsu H., et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008, 62:316-320.
17. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
18. Bartel D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
19. Fazi F., Nervi C., MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination. Cardiovasc Res 2008, 79:553-561.
20. Kent O.A., Mendell J.T. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006, 25:6188-6196.
21. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
22. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801.
23. Cummins J.M., Velculescu V.E. Implications of micro-RNA profiling for cancer diagnosis. Oncogene 2006, 25:6220-6227.
24. Fazi F., Fontemaggi G. MicroRNAs and lymph node metastatic disease in lung cancer. Thorac Surg Clin 2012, 22:167-175.
25. Storey J.D. A direct approach to false discovery rates. J. R. Statist. Soc. B 2002, 64:479-498.
26. Cheadle C., Vawter M.P., Freed W.J., Becker K.G. Analysis of microarray data using z score transformation. J Mol Diagn 2003, 5:73-81.
27. Okumura M., Ohta M., Tateyama H., Nakagawa K., Matsumura A., Maeda H., et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002, 94:624-632.
28. Chen G., Marx A., Chen W.H., Yong J., Puppe B., Stroebel P., et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002, 95:420-429.
29. Strobel P., Bauer A., Puppe B., Kraushaar T., Krein A., Toyka K., et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004, 22:1501-1509.
30. Strobel P., Hohenberger P., Marx A. Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol 2010, 5:S286-S290.
31. Cho W.C., Chow A.S., Au J.S. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 2011, 8:125-131.
32. Guo Y.H., Zhang C., Shi J., Xu M.H., Liu F., Yuan H.H., et al. Abnormal activation of the EGFR signaling pathway mediates the downregulation of miR145 through the ERK1/2 in non-small cell lung cancer. Oncol Rep 2014, 31:1940-1946.
33. Harnath T., Marx A., Strobel P., Bolke E., Willers R., Gripp S. Thymoma-a clinico-pathological long-term study with emphasis on histology and adjuvant radiotherapy dose. J Thorac Oncol 2012, 7:1867-1871.
34. Huang B., Belharazem D., Li L., Kneitz S., Schnabel P.A., Rieker R.J., et al. Anti-Apoptotic signature in thymic squamous cell carcinomas - functional relevance of anti-apoptotic BIRC3 expression in the thymic carcinoma cell line 1889c. Front Oncol 2013, 3:316.
35. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
36. Cioce M., Ganci F., Canu V., Sacconi A., Mori F., Canino C. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene 2013, 10.1038/onc.2013.476.
37. Weissferdt A., Wistuba I.I., Moran C.A. Molecular aspects of thymic carcinoma. Lung Cancer 2012, 78:127-132.
38. Breinig M., Mayer P., Harjung A., Goeppert B., Malz M., Penzel R., et al. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clin Cancer Res 2011, 17:2237-2249.